Compass Pathways (NASDAQ: CMPS) is a mental health care company developing new therapies for difficult- to-treat conditions. It focuses on its COMP360 psilocybin therapy for treatment-resistant depression (TRD). This is a condition where patients do not respond to standard depression treatments. The company has a market capitalization of approximately $1.25 billion. As reported by Benzinga, the 26-week results from the study of nearly 600 patients show strong performance. The data shows that 39% of patients ...